JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Darby Anderson, the Executive Vice President and Chief Legislative Officer of Addus HomeCare Corp (NASDAQ:ADUS), recently sold a portion of his common stock holdings in the company. The transaction comes as the healthcare provider, with a market capitalization of $1.73 billion, has seen its stock decline by approximately 15% over the past week. According to a filing with the Securities and Exchange Commission, Anderson offloaded 418 shares on February 25, 2025, at a price of $99.88 per share. The total value of the transaction amounted to $41,749.
Following this sale, Anderson retains ownership of 44,144 shares in Addus HomeCare. The sale was conducted under a pre-arranged 10b5-1 trading plan, with the proceeds intended to cover tax obligations arising from the vesting of restricted stock awards.
In other recent news, Addus HomeCare Corporation reported its fourth-quarter 2024 earnings, surpassing expectations with earnings per share of $1.38 and revenue of $297.1 million, both exceeding analyst forecasts. Despite these strong results, Addus HomeCare’s stock experienced a decline, attributed to investor concerns about broader market conditions and potential Medicaid policy changes. The company completed a significant acquisition of Gentiva, which is expected to contribute positively to its financial performance in the future. Analyst firms have provided mixed updates on Addus HomeCare, with KeyBanc maintaining an Overweight rating and a price target of $150, while Stephens and Raymond (NSE:RYMD) James have adjusted their price targets to $142 and $120, respectively, citing concerns over Medicaid cuts.
Addus HomeCare’s strategic focus remains on mergers and acquisitions, with a commitment to maintaining a strong growth trajectory and a diversified pipeline. The company’s role within the Medicaid system is considered relatively insulated from potential funding cuts, with only a small percentage of revenue potentially impacted by changes in Federal Medical (TASE:BLWV) Assistance Percentages (FMAP). Analysts at KeyBanc and Raymond James recognize the company’s strong execution and cash flow generation, suggesting optimism for future growth despite current market uncertainties. Addus HomeCare’s outlook for 2025 includes a target of 10% annual revenue growth and continued strategic acquisitions to enhance its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.